Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines approved by the European Medicines Agency and the US Food and Drug Administration that have been scored and published by ESMO.

ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 135
3 156
2 55
1 24
NEB 4
Curative setting
A 54
C 3
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 39
Endocrine Tumours 21
Gastrointestinal Cancers 76
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 13
Skin Cancers 29
Thoracic Malignancies 86
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 11
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Axitinib - Sorafenib Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or cytokine AXIS
    Genitourinary Cancers
    		 Renal cell cancer - AXIS

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pazopanib - Sunitinib First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease COMPARZ
    Genitourinary Cancers
    		 Renal cell cancer - COMPARZ

    4

    PRELIMINARY SCORE

    • NI

    ADJUSTMENTS

    SCORE

    • F2c
      4
    Sunitinib - Interferon Treatment of advanced/metastatic renal cell carcinoma in adults
    Genitourinary Cancers
    		 Renal cell cancer - -

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Sorafenib - Placebo Patients with advanced RCC who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy TARGET
    Genitourinary Cancers
    		 Renal cell cancer - TARGET

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Everolimus - Placebo (Crossover allowed) Patients with advanced RCC, whose disease has progressed on or after treatment with VEGF-targeted therapy RECORD-1
    Genitourinary Cancers
    		 Renal cell cancer - RECORD-1

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pazopanib - Placebo (Crossover allowed) First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease Study VEG105192
    Genitourinary Cancers
    		 Renal cell cancer - Study VEG105192

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Bevacizumab Interferon Interferon + placebo In combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer AVOREN
    Genitourinary Cancers
    		 Renal cell cancer - AVOREN

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Cabozantinib - Everolimus As monotherapy as the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF) - targeted therapy METEOR
    Genitourinary Cancers
    		 Renal cell cancer - METEOR

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Lenvatinib Everolimus Everolimus Treatment of adults with advanced renal cell carcinoma in combination with everolimus following one prior vascular endothelial growth factor (VEGF)-targeted therapy
    Genitourinary Cancers
    		 Renal cell cancer - -

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Cabozantinib - Placebo As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib CELESTIAL
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - CELESTIAL

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Regorafenib - Placebo As monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib RESORCE
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - RESORCE

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Nivolumab + ipilimumab - Sunitinib First-line treatment of adult patients with intermediate/poor-risk advanced RCC CheckMate 214
    Genitourinary Cancers
    		 Renal cell cancer - CheckMate 214

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Tivozanib - Sorafenib First-line treatment and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy TIVO-1
    Genitourinary Cancers
    		 Renal cell cancer - TIVO-1

    1

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      1
    FLOT (docetaxel, oxaliplatin, 5-FU, folinic acid) - 5-FU or capecitabine + cisplatin + epirubicin Peri-operative locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma FLOT4
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - FLOT4

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Gemcitabine Capecitabine Gemcitabine Adjuvant therapy following resection for pancreatic cancer ESPAC-4
    Gastrointestinal Cancers
    		 Pancreatic cancer - ESPAC-4

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    mFOLFIRINOX - Gemcitabine Adjuvant therapy following resection for pancreatic cancer PRODIGE 24/CCTG PA.6
    Gastrointestinal Cancers
    		 Pancreatic cancer - PRODIGE 24/CCTG PA.6

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Nanoliposomal irinotecan 5-FU/LV 5-FU/LV Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5 fluorouracil (5 FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy NAPOLI-1
    Gastrointestinal Cancers
    		 Pancreatic cancer - NAPOLI-1

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Osimertinib - Gefitinib or erlotinib Previously untreated EGFR mutated (exon 19 deletion or L858R) FLAURA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ (exon 19 deletion or L858R) FLAURA

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Alectinib - Crizotinib As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). ALEX
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ALEX

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Alectinib - Chemotherapy (pemetrexed or docetaxel) As monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC previously treated with crizotinib ALUR
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ALUR

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Atezolizumab - Docetaxel As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy OAK
    Thoracic Malignancies
    		 Squamous or non-squamous non-small-cell lung cancer - OAK

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Ceritinib - Chemotherapy (pemetrexed or docetaxel) Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib ASCEND-5
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ASCEND-5

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Ceritinib - Chemotherapy Frist-line treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) stage IIIB/IV ASCEND-4
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ASCEND-4

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Crizotinib - Single arm Treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC) PROFILE 1001
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ROS1+ PROFILE 1001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Dab/Tram (dabrafenib and trametinib) - Single arm Advanced NSCLC with a BRAF V600 mutation
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer BRAF V600E (Pretreated (Cohort B)) -

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Dab/Tram (dabrafenib and trametinib) - Single arm Advanced NSCLC with a BRAF V600 mutation
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer BRAF V600E (Treatment-naïve (Cohort C)) -

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Pembrolizumab Pemetrexed + platinum chemotherapy Placebo + pemetrexed + platinum chemotherapy In combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive tumour mutations KEYNOTE-189
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - KEYNOTE-189

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Pertuzumab Standard adjuvant ChT + 1 year of treatment with trastuzumab Placebo + standard adjuvant ChT + 1 year of treatment with trastuzumab Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (node-positive or hormone receptor-negative disease) APHINITY
    Breast Cancer
    		 Early Breast Cancer HER2+ APHINITY

    C

    PRELIMINARY SCORE

    • iDFS

    ADJUSTMENTS

    SCORE

    • F1

      C
    Neratinib - Placebo Extended adjuvant treatment of patients with early-stage hormone receptor-positive HER2-positive breast cancer who completed adjuvant trastuzumab-based therapy ExteNET
    Breast Cancer
    		 Early Breast Cancer HR+ HER2+ ExteNET

    NEB

    PRELIMINARY SCORE

    • NEB

    ADJUSTMENTS

    SCORE

    • F1
      NEB
    Lenvatinib - Placebo As monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI) SELECT
    Endocrine Tumours
    		 Thyroid cancer - differentiated MKI targeting VEGFR1, VEGFR2 and VEGFR3 SELECT

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.